| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| TREND | 650 | Novartis Pharmaceuticals | 2015 |
Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: Results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57-65. https://www.aaojournal.org/article/S0161-6420(17)31025-4/fulltext |
|